Agree with you on funding being the reason.
Was there a phase2a study that predated your referenced phase 2 trial on Ionis-GHR-LRX (Cimdelirsen)?
I quote this from the Ionis 2019 Ann Report, top of page 18: (https://ir.ionispharma.com/static-files/13a2c945-e305-4e72-917e-5582de2500ae)
”In November 2018, we initiated the Phase 2 proof-of-concept clinical study of IONIS-GHR-LRX in acromegaly patients. The study is randomised, double-blind, placebo-controlled, multi-center study on acromegaly patients uncontrolled on select long-acting somatostatin receptor ligands.”
- Forums
- ASX - By Stock
- PER
- For General Information
For General Information, page-3227
Featured News
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
8.0¢ |
Change
0.001(1.27%) |
Mkt cap ! $82.94M |
Open | High | Low | Value | Volume |
8.0¢ | 8.3¢ | 7.9¢ | $461.5K | 5.711M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 844186 | 8.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.2¢ | 292500 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 844186 | 0.080 |
8 | 506274 | 0.079 |
7 | 678354 | 0.078 |
8 | 1027327 | 0.077 |
4 | 346421 | 0.076 |
Price($) | Vol. | No. |
---|---|---|
0.082 | 292500 | 1 |
0.083 | 230000 | 2 |
0.084 | 118750 | 2 |
0.085 | 187500 | 2 |
0.086 | 250000 | 1 |
Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |
The Watchlist
EQN
EQUINOX RESOURCES LIMITED.
Zac Komur, MD & CEO
Zac Komur
MD & CEO
SPONSORED BY The Market Online